Clinical Trials

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06149286 2026-04-13

OLYMPIA-5

Phase 3 Recruiting

470 enrolled

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT05888493 2026-03-24

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence

NCT07460362 2026-03-10

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

43 enrolled

Phase 3 Active not recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT04712097 2026-02-04

Celestimo

478 enrolled

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT02390869 2025-12-02

FIL_RENOIR12

128 enrolled

Lymphoma, Follicular, Recurrence

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05626322 2025-09-05

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1/2 Terminated

6 enrolled 17 charts

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07126236 2025-08-17

REPIFIR

80 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06651853 2025-07-23

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

22 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06414148 2025-06-05

EpLCART

40 enrolled

Lymphoma, Recurrence, Neoplasm, Residual

NCT04036448 2025-03-11

RevlimidPMS

Completed

28 enrolled

LymphoidMyeloid

Lymphoma, Follicular, Myelodysplastic Syndromes, Recurrence, Lymphoma, Mantle-Cell

NCT03647124 2025-03-04

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Completed

105 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT01199575 2024-08-15

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

30 enrolled 12 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00799513 2024-04-10

RV-NHL-PI351

48 enrolled 17 charts

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02341014 2024-04-04

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Phase 1/2 Completed

27 enrolled 13 charts

Lymphoma, Recurrence, Lymphoma, T-Cell

NCT02600897 2023-12-26

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Completed

114 enrolled 34 charts

Lymphoma, Follicular, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05797948 2023-04-04

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase NA Unknown

20 enrolled

Recurrence, Lymphoma, B-Cell

NCT04113226 2023-02-08

Relyage

Phase 2 Unknown

114 enrolled

LymphoidSarcoma

Recurrence, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT03302728 2022-05-19

EpiBrentlen

6 enrolled

DermatologicLymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT01956695 2020-12-17

REVRI

45 enrolled

Lymphoma, Recurrence

NCT01542918 2020-08-11

Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

14 enrolled

Lymphoma, Recurrence, Intraocular Lymphoma

NCT04329130 2020-04-24

Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Phase 2 Unknown

44 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT01788189 2020-02-26

LeMLAR

Phase 1/2 Completed

37 enrolled

Lymphoma, Recurrence, Lymphoma, B-Cell

NCT04109872 2020-02-05

Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.

Unknown

25 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2/3 Completed

111 enrolled 20 charts

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00419250 2019-11-08

A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

52 enrolled

Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01729104 2019-10-22

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Phase 1 Terminated

18 enrolled

Lymphoma, Recurrence, Lymphoma, Mantle-Cell

NCT02060656 2019-09-19

LEGEND

Phase 2 Unknown

92 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00963105 2018-10-31

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

104 enrolled 18 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02983097 2018-01-19

R²-DHAP

Phase 1/2 Terminated

34 enrolled

Burkitt Lymphoma, Lymphoma, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01121757 2016-09-12

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Phase 2 Terminated

11 enrolled 12 charts

Lymphoma, Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT01185262 2013-09-30

LLC-LENAR-08

25 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00968331 2012-08-27

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Terminated

25 enrolled